Successful companies continue to thrive by adopting organic and acquisition based growth strategies
There are more than 3,200 corporate groups worldwide engaged in manufacturing active pharmaceutical ingredients (APIs), participating in an estimated $182 billion market. Manufacturers vary in their experience of producing APIs for use in regulated markets and only 13% of groups have demonstrated consistent, long-term ability to do so. Margins are small, and manufacturers are under tremendous pressures from many challenges in the global healthcare environment. Successful companies continue to develop by exploring several organic and acquisition-based growth strategies.
This whitepaper explores the global API manufacturing landscape, challenges for manufacturers, and the future outlook of the industry.
Complete the form to access the full report.